Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nalbuphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 11/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 10/20 | 1.00 |
| ▸ | OPRD1 known ✓ | P41143 | 9/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nalbuphine SCHEMBL6123677 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL12646324 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL13906700 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL12588894 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL13906701 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL19767567 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL18458094 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL19385893 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL21090866 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL12566029 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2147920-B1 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | MALLINCKRODT LLC (US) | 2016-08-31 | — | — | EP | claimed |
| US-9415044-B2 | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts | MALLINCKRODT LLC (US) | 2016-08-16 | — | — | US | claimed |
| US-20150164886-A9 | Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts | MALLINCKRODT INC. (US) | 2015-06-18 | — | — | US | claimed |
| EP-2137189-B1 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT LLC (US) | 2015-05-06 | — | — | EP | claimed |
| US-20150099773-A1 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | VTESSE LLC | 2015-04-09 | — | — | US | claimed |
| US-20100035910-A1 | Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts | MALLINCKRODT INC. (US) | 2010-02-11 | — | — | US | claimed |
| EP-2147920-A2 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | Mallinckrodt Inc. (US) | 2010-01-27 | — | — | EP | claimed |
| EP-2137189-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | Mallinckrodt Inc. (US) | 2009-12-30 | — | — | EP | claimed |
| EP-1562953-B1 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT INC (US) | 2009-09-30 | — | — | EP | claimed |
| WO-2008109156-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT INC. (US) | 2008-09-12 | — | — | WO | claimed |
| US-7285665-B2 | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts | MALLINCKRODT INC. (US) | 2007-10-23 | — | — | US | claimed |
| US-20060014771-A1 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | SpecGx LLC | 2006-01-19 | — | — | US | claimed |
| US-20210330667-A1 | TOPICAL COMPOSITION OF NALBUPHINE AND METHOD FOR TREATING PRURITUS CONDITION, PAIN, OR INFLAMMATORY CONDITION BY USING THE SAME | LUMOSA THERAPEUTICS CO., LTD. (TW) | 2021-10-28 | — | — | US | disclosed |
| EP-3222293-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | Nektar Therapeutics (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2620163-B1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2628489-B1 | PEG oligomer-fentanyl conjugates | NEKTAR THERAPEUTICS (US) | 2017-03-01 | — | — | EP | disclosed |
| US-4282215-A | Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-08-04 | — | — | US | disclosed |
| EP-0024690-A1 | Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-03-11 | — | — | EP | disclosed |
| EP-0019282-A1 | Analgesic mixture of nalbuphine and acetaminophen | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-11-26 | — | — | EP | disclosed |
| US-4089855-A | Process for the stereoselective reduction of 6- and 8-keto morphine and morphinan derivatives with formamidinesulfinic acid and compounds obtained thereby | CORNELL RESEARCH FOUNDATION, INC. (US) | 1978-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014771-A1 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | TTN, PML, EMD | OPRM1 45/4885OPRK1 245/4885OPRD1 164/4885 |
| US-20100035910-A1 | Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts | RAN, RANBP1, NCLN | OPRM1 60/4885OPRK1 527/4885OPRD1 406/4885 |
| US-20150099773-A1 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | RAN, RANBP1, NCLN | OPRM1 60/4885OPRK1 527/4885OPRD1 406/4885 |
| US-20150164886-A9 | Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts | RAN, RANBP1, NCLN | OPRM1 60/4885OPRK1 527/4885OPRD1 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.